Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology (ACTC)

Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 7/28/2014 10:16:40 PM - Followers: 632 - Board type: Free - Posts Today: 28

Advanced Cell Technology, Inc. (ACTC)







Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662



Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing: http://www.youtube.com/watch?v=MPBiNlUFIww#t=55s

For more information visit www.AdvancedCell.com




Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#69859   Well said-there are some truly pitiful people in elysse1kittycat 07/28/14 10:16:40 PM
#69858   Same M O. Dump at the open.. Gastrodamas 07/28/14 09:42:20 PM
#69857   well said. homeslice10 07/28/14 08:58:04 PM
#69856   $ACTC has a sharp downfall... iamcool1668 07/28/14 08:05:52 PM
#69855   Advanced Cell Technology down -6.86% to .0695 on ddls 07/28/14 07:00:59 PM
#69851   Sure. Because it trades on OTC which is wellsm 07/28/14 04:11:37 PM
#69850   Anyone can tell me please , Why it Gubbar 07/28/14 02:46:01 PM
#69849   Advanced Cell Technology is the classic "do not ddls 07/28/14 12:59:51 PM
#69848   I rightfully predicted some weeks back that before elysse1kittycat 07/28/14 12:26:40 PM
#69847   ACT's new CEO likely lookng for new financing ddls 07/28/14 12:07:21 PM
#69846   I thought the 7s would hold a little Killtoy 07/28/14 12:01:28 PM
#69845   ACTC's as popular as polution. ddls 07/28/14 11:38:18 AM
#69842   On the message board of Wottens previous company blaydonracer 07/28/14 11:04:22 AM
#69840   If only PPS would move up as fast guy3 07/28/14 10:32:15 AM
#69839   ACTC GROOMS NEW SET OF INVESTOR'S FOR WAX ddls 07/28/14 10:29:37 AM
#69838   ADVANCED CELL PAYS OVER $4M FOR STOCK SCHEME ddls 07/28/14 10:28:25 AM
#69837   "We continue to pay are debt financing in ddls 07/28/14 10:26:26 AM
#69836   I really don't mind this gentle slide in MR MUTT 07/28/14 10:20:56 AM
#69835   Advanced Cell Technology continues to move the trials ddls 07/28/14 10:19:35 AM
#69834   ACTC "light at the end of the tunnel" :) chuckanutman 07/28/14 09:26:35 AM
#69833   <<Finally seeing light at the end of the chadm 07/28/14 08:35:08 AM
#69832   Finally seeing light at the end of the Booski 07/28/14 07:48:07 AM
#69831   With any luck come Monday morning we wont Gastrodamas 07/27/14 08:12:28 PM
#69830   Welcome aboard. elysse1kittycat 07/27/14 02:16:39 PM
#69829   Advanced Cell Technology needs more than just LPC, ddls 07/27/14 01:41:29 PM
#69828   "We continue to pay our debt in shares ddls 07/27/14 01:37:01 PM
#69827   Just a matter of time before the LPC BrownRickRoss 07/26/14 08:58:24 PM
#69826   Most definitely. andyshow 07/26/14 08:14:14 PM
#69825   Imo whether a poster agrees that the company elysse1kittycat 07/26/14 07:46:33 PM
#69824   Wotton is living proof of the direction we andyshow 07/26/14 07:17:02 PM
#69822   Don't forget we also have the kryptonite factor elysse1kittycat 07/26/14 05:02:58 PM
#69821   Absolutely not IMO. When the dam breaks and andyshow 07/26/14 04:54:52 PM
#69820   Do you think that we should be concerned elysse1kittycat 07/26/14 04:48:50 PM
#69819   Amazing ACTC safety profile. https://www.youtube.com/watch?v=sq3cQVrnaWs chuckanutman 07/26/14 04:18:50 PM
#69818   Excellent post chuck. The great thing about this andyshow 07/26/14 03:07:05 PM
#69817   Quote: "Are we there yet, are we chuckanutman 07/26/14 02:56:45 PM
#69816   The fact that I haven't seen one negative elysse1kittycat 07/26/14 12:45:02 PM
#69815   I am STILL holding ALL my ORIGINAL LODE MAKING ME RICH 07/26/14 12:39:20 PM
#69814   ACTC quote: "The company has NO DEBT" ACTC chuckanutman 07/26/14 12:26:34 PM
#69813   ACTC turning around and heading back up truck. chuckanutman 07/25/14 10:09:47 PM
#69812  Restored As a last resort for funds maybe investor's ddls 07/25/14 09:12:12 PM
#69811   Maybe ACTC should seek out financing in the ddls 07/25/14 08:11:57 PM
#69809   Thankyou for the kind report. Have you ever chuckanutman 07/25/14 04:42:40 PM
#69808   HAPPY HOUR HETE 4-5 free tools at the sports guy 07/25/14 04:37:17 PM
#69807   Just think folks-all ACTC has to do is elysse1kittycat 07/25/14 04:28:20 PM
#69806   "Your comments are not even factual." elysse1kittycat 07/25/14 04:21:15 PM
#69805   The Advanced Cell Technology Sales staff is at ddls 07/25/14 04:18:36 PM
#69804   If there was a stock symbol FOS, I elysse1kittycat 07/25/14 04:13:11 PM
#69803   Also, looks like the ACTC super sales staff ddls 07/25/14 04:09:36 PM
#69802   It looks like for now the parameters/trading range elysse1kittycat 07/25/14 04:02:53 PM